Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK4 | Q13043 | 16/20 | 1.00 |
| ▸ | AURKA | O14965 | 3/20 | 0.60 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.60 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.60 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.60 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.60 |
| ▸ | PIK3C2G | O75747 | 2/20 | 0.60 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.60 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.60 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.58 |
| ▸ | ABL1 | P00519 | 1/20 | 0.58 |
| ▸ | JAK1 | P23458 | 1/20 | 0.58 |
| ▸ | TYK2 | P29597 | 1/20 | 0.58 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.58 |
| ▸ | RIPK4 | P57078 | 1/20 | 0.58 |
| ▸ | STK3 | Q13188 | 1/20 | 0.58 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.58 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.58 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.58 |
| ▸ | MAP3K3 | Q99759 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23998720 | 0.96 | STK4 (1.00) | STK4AURKAPIK3CGAURKBDCLK1 | |
| SCHEMBL23998712 | 0.96 | STK4 (1.00) | STK4AURKAPIK3CGAURKBDCLK1 | |
| SCHEMBL23998718 | 0.95 | STK4 (1.00) | STK4AURKAPIK3CGAURKBDCLK1 | |
| SCHEMBL25060514 | 0.84 | STK4 (0.73) | STK4AURKAPIK3CGAURKBDCLK1 | |
| SCHEMBL24928824 | 0.82 | STK4 (0.76) | STK4AURKAPIK3CGAURKBPIK3CD | |
| SCHEMBL29322630 | 0.82 | STK4 (0.69) | STK4AURKAPIK3CGAURKBDCLK1 | |
| SCHEMBL25060508 | 0.81 | STK4 (0.75) | STK4AURKAPIK3CGAURKBDCLK1 | |
| SCHEMBL25766805 | 0.81 | STK4 (0.68) | STK4AURKAPIK3CGAURKBDCLK1 | |
| SCHEMBL25060523 | 0.81 | STK4 (0.74) | STK4AURKAPIK3CGAURKBDCLK1 | |
| SCHEMBL25118928 | 0.80 | STK4 (0.75) | STK4AURKAPIK3CGAURKBDCLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4400582-A1 | CULTURE MEDIUM FOR HEPATOMA ORGANOID CULTURE, HEPATOMA ORGANOID CULTURE METHOD, AND APPLICATION OF HEPATOMA ORGANOID | Precedo Pharmaceuticals Co., Ltd. (CN) | 2024-07-17 | — | — | EP | disclosed |
| US-20230235283-A1 | CULTURE MEDIUM FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA EPITHELIAL CELLS, CULTURE METHOD, AND APPLICATION THEREOF | PRECEDO PHARMACEUTICALS CO., LTD (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230235283-A1 | CULTURE MEDIUM FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA EPITHELIAL CELLS, CULTURE METHOD, AND APPLICATION THEREOF | PRECEDO PHARMACEUTICALS CO., LTD (CN) | 2023-07-27 | — | — | US | disclosed |
| WO-2023060695-A1 | CULTURE MEDIUM AND CULTURE METHOD FOR SUSPENDED CULTURE OF LIVER CANCER ORGANOIDS | 合肥中科普瑞昇生物医药科技有限公司 | 2023-04-20 | — | — | WO | disclosed |
| WO-2023060764-A1 | CULTURE MEDIUM FOR PRIMARY CELL OF GASTRIC CARCINOMA, AND CULTURE METHOD THEREFOR | 合肥中科普瑞昇生物医药科技有限公司 | 2023-04-20 | — | — | WO | disclosed |
| WO-2023060643-A1 | CULTURE MEDIUM AND CULTURE METHOD FOR INTESTINAL CANCER ORGANOID | 合肥中科普瑞昇生物医药科技有限公司 | 2023-04-20 | — | — | WO | disclosed |
| WO-2023060681-A1 | CULTURE MEDIUM AND CULTURE METHOD FOR PRIMARY CERVICAL CANCER CELLS | 合肥中科普瑞昇生物医药科技有限公司 | 2023-04-20 | — | — | WO | disclosed |
| WO-2023060710-A1 | CULTURE MEDIUM AND CULTURE METHOD FOR GASTRIC CANCER ORGANOIDS | 合肥中科普瑞昇生物医药科技有限公司 | 2023-04-20 | — | — | WO | disclosed |
| WO-2023060709-A1 | ESOPHAGEAL CANCER ORGANOID CULTURE MEDIUM AND CULTURE METHOD AND USE THEREOF | 合肥中科普瑞昇生物医药科技有限公司 | 2023-04-20 | — | — | WO | disclosed |
| WO-2023060677-A1 | CULTURE MEDIUM, CULTURE METHOD AND USE OF PRIMARY OVARIAN CANCER CELLS | 合肥中科普瑞昇生物医药科技有限公司 | 2023-04-20 | — | — | WO | disclosed |
| WO-2023060774-A1 | CULTURE MEDIUM FOR CERVICAL CANCER ORGANOIDS, AND CULTURE METHOD AND APPLICATION THEREOF | 合肥中科普瑞昇生物医药科技有限公司 | 2023-04-20 | — | — | WO | disclosed |
| WO-2023060676-A1 | CULTURE MEDIUM AND CULTURE METHOD FOR OVARIAN CANCER ORGANOID, AND APPLICATION THEREOF | 合肥中科普瑞昇生物医药科技有限公司 | 2023-04-20 | — | — | WO | disclosed |
| EP-4137565-A1 | CULTURE MEDIUM FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA EPITHELIAL CELLS, CULTURE METHOD, AND APPLICATION THEREOF | Precedo Pharmaceuticals Co., Ltd. (CN) | 2023-02-22 | — | — | EP | disclosed |
| WO-2023004888-A1 | CULTURE MEDIUM FOR CULTURING ORAL CANCER ORGANOIDS, AND CULTURE METHOD THEREFOR AND USE THEREOF | 合肥中科普瑞昇生物医药科技有限公司 | 2023-02-02 | — | — | WO | disclosed |
| WO-2023279455-A1 | CULTURE MEDIUM AND CULTURE METHOD FOR LUNG CANCER EPITHELIAL CELLS, AND APPLICATION THEREOF | 合肥中科普瑞昇生物医药科技有限公司 | 2023-01-12 | — | — | WO | disclosed |
| WO-2021237905-A1 | CULTURE MEDIUM FOR LARYNGEAL CANCER EPITHELIAL CELLS, CULTURE METHOD, AND APPLICATION THEREOF | 中科院合肥技术创新工程院 | 2021-12-02 | — | — | WO | disclosed |
| US-20210346406-A1 | MST1 KINASE INHIBITOR AND USE THEREOF | HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES (CN) | 2021-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346406-A1 | MST1 KINASE INHIBITOR AND USE THEREOF | MST1, MST1R, STK11 | STK4 10/4885AURKA 388/4885PIK3CG 1300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.